首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
Pyogenic Hepatic Abscess in an Immunocompetent Patient With Poor Oral Health and COVID-19 Infection. 口腔健康不良和新冠肺炎感染的免疫功能正常患者的致脓性肝脓肿。
Pub Date : 2023-06-01 Epub Date: 2023-06-15 DOI: 10.12788/fp.0382
Manuel Vazquez, Alana Vassil, Igor Sirotkin

Background: Pyogenic hepatic abscess (PHA) is a collection of pus in the liver caused by bacterial infection of the liver parenchyma. PHA is more common in immunosuppressed individuals and those with diabetes mellitus, cancer, and liver transplant.

Case presentation: We present a rare case of PHA with Fusobacterium nucleatum in an immunocompetent patient with poor oral health, history of diverticulitis, and recent COVID-19 infection whose only symptoms were chest pain and a 4-week history of fever and malaise. The source of infection in this patient was likely dental caries and periodontal disease, with COVID-19 infection playing a role as a red herring in this patient's disease progression, delaying diagnosis.

Conclusions: Diagnosis and treatment of PHA must be prompt with drainage and empiric anaerobic coverage followed by a more tailored antibiotic regimen if indicated by culture and further drainage if indicated by computed tomography.

背景:化脓性肝脓肿(PHA)是由肝实质细菌感染引起的肝脏脓液聚集。PHA在免疫抑制个体和糖尿病、癌症和肝移植患者中更常见。病例介绍:我们报告了一例罕见的有核梭杆菌PHA病例,患者具有免疫功能,口腔健康不良,有乳头炎病史,最近感染了新冠肺炎,其唯一症状是胸痛和4周的发烧和不适史。该患者的感染源可能是龋齿和牙周病,新冠肺炎感染在该患者的疾病进展中起到转移注意力的作用,从而推迟了诊断。结论:PHA的诊断和治疗必须及时进行引流和经验性厌氧覆盖,如果通过培养指示,则采用更具针对性的抗生素方案,如果通过计算机断层扫描指示,则进一步引流。
{"title":"Pyogenic Hepatic Abscess in an Immunocompetent Patient With Poor Oral Health and COVID-19 Infection.","authors":"Manuel Vazquez,&nbsp;Alana Vassil,&nbsp;Igor Sirotkin","doi":"10.12788/fp.0382","DOIUrl":"10.12788/fp.0382","url":null,"abstract":"<p><strong>Background: </strong>Pyogenic hepatic abscess (PHA) is a collection of pus in the liver caused by bacterial infection of the liver parenchyma. PHA is more common in immunosuppressed individuals and those with diabetes mellitus, cancer, and liver transplant.</p><p><strong>Case presentation: </strong>We present a rare case of PHA with <i>Fusobacterium nucleatum</i> in an immunocompetent patient with poor oral health, history of diverticulitis, and recent COVID-19 infection whose only symptoms were chest pain and a 4-week history of fever and malaise. The source of infection in this patient was likely dental caries and periodontal disease, with COVID-19 infection playing a role as a red herring in this patient's disease progression, delaying diagnosis.</p><p><strong>Conclusions: </strong>Diagnosis and treatment of PHA must be prompt with drainage and empiric anaerobic coverage followed by a more tailored antibiotic regimen if indicated by culture and further drainage if indicated by computed tomography.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584407/pdf/fp-40-06-182.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Pharmacist Interventions at an Outpatient US Coast Guard Clinic. 美国海岸警卫队门诊部药剂师干预措施的影响。
Pub Date : 2023-06-01 Epub Date: 2023-06-14 DOI: 10.12788/fp.0383
Fengyee Zhou, Zachary Woodward

Background: US Coast Guard (USCG) active-duty service members (ADSMs) are required to maintain medical readiness to maximize operational success. USCG pharmacists serve the traditional pharmacist role while maintaining oversight of regional pharmaceutical services. This study aimed to quantify the number, duty status impact, and replicability of medication interventions made by one pharmacist at the USCG Base Alameda clinic in California over 6 months.

Methods: Medication interventions made at the USCG Base Alameda clinic from July 1, 2021, to December 31, 2021, were categorized as a drug therapy problem (DTP) or non-DTP. Each DTP was further evaluated in a retrospective record review by a panel of USCG pharmacists to assess 2 additional factors: duty status severity (potential to affect duty status) and replicability (potential for the same intervention to be made in the absence of access to the patient health record).

Results: USCG Base Alameda pharmacy dispensed 1751 prescriptions and made 116 interventions (7%), of which 111 (96%) were accepted by the prescriber. Of the interventions, 64 (55%) were DTPs, and 14 of those (22%) had potential to change duty status, and 18 DTPs (28%) were made because the pharmacist had access to the health record.

Conclusions: Pharmacists' role in USCG clinics includes collaborating with the patient care team to make medication interventions that have significant impact on ADSMs' wellness and the USCG mission.

背景:美国海岸警卫队(USCG)现役军人(ADSM)需要保持医疗准备状态,以最大限度地提高作战成功率。南加州大学药剂师在履行传统药剂师职责的同时,对区域药品服务进行监督。本研究旨在量化加利福尼亚州阿拉米达USCG基地诊所一名药剂师在6个月内进行的药物干预的数量、职责状态影响和可复制性。方法:2021年7月1日至2021年12月31日在南加州大学阿拉米达基地诊所进行的药物干预被归类为药物治疗问题(DTP)或非DTP。USCG药剂师小组在回顾性记录审查中对每个DTP进行了进一步评估,以评估2个额外因素:职责状态的严重性(可能影响职责状态)和可复制性(在无法访问患者健康记录的情况下可能进行相同干预)。结果:USCG基地阿拉米达药房开出了1751张处方,进行了116次干预(7%),其中111例(96%)被处方医生接受。在干预措施中,64项(55%)是DTP,其中14项(22%)有可能改变职责状态,18项(28%)是因为药剂师可以访问健康记录而进行的。结论:药剂师在USCG诊所的作用包括与患者护理团队合作,进行药物干预,对ADSM的健康和USCG使命产生重大影响。
{"title":"Impact of Pharmacist Interventions at an Outpatient US Coast Guard Clinic.","authors":"Fengyee Zhou,&nbsp;Zachary Woodward","doi":"10.12788/fp.0383","DOIUrl":"https://doi.org/10.12788/fp.0383","url":null,"abstract":"<p><strong>Background: </strong>US Coast Guard (USCG) active-duty service members (ADSMs) are required to maintain medical readiness to maximize operational success. USCG pharmacists serve the traditional pharmacist role while maintaining oversight of regional pharmaceutical services. This study aimed to quantify the number, duty status impact, and replicability of medication interventions made by one pharmacist at the USCG Base Alameda clinic in California over 6 months.</p><p><strong>Methods: </strong>Medication interventions made at the USCG Base Alameda clinic from July 1, 2021, to December 31, 2021, were categorized as a drug therapy problem (DTP) or non-DTP. Each DTP was further evaluated in a retrospective record review by a panel of USCG pharmacists to assess 2 additional factors: duty status severity (potential to affect duty status) and replicability (potential for the same intervention to be made in the absence of access to the patient health record).</p><p><strong>Results: </strong>USCG Base Alameda pharmacy dispensed 1751 prescriptions and made 116 interventions (7%), of which 111 (96%) were accepted by the prescriber. Of the interventions, 64 (55%) were DTPs, and 14 of those (22%) had potential to change duty status, and 18 DTPs (28%) were made because the pharmacist had access to the health record.</p><p><strong>Conclusions: </strong>Pharmacists' role in USCG clinics includes collaborating with the patient care team to make medication interventions that have significant impact on ADSMs' wellness and the USCG mission.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584406/pdf/fp-40-06-174.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacist-Led Antimicrobial Stewardship and Antibiotic Use in Hospitalized Patients With COVID-19. 药剂师-新冠肺炎住院患者的抗菌药物管理和抗生素使用。
Pub Date : 2023-06-01 Epub Date: 2023-06-22 DOI: 10.12788/fp.0380
Selena N Pham, Taylor M Hori, Ashfaq Shafiq

Background: During the COVID-19 pandemic, a significant increase in the use of empiric antibiotic therapy has been observed especially in patients hospitalized with COVID-19. Improving antibiotic prescribing is one of the main goals of the antimicrobial stewardship program (ASP). The ASP pharmacists have a scope of practice that authorizes changes in anti-infective therapy.

Methods: We aimed to describe antibiotic prescribing in patients hospitalized with COVID-19 at Veterans Affairs Southern Nevada Healthcare System with a pharmacist-led ASP and to determine the prevalence of bacterial coinfection in this patient population. We performed a retrospective chart review of patients admitted to the facility from November 1, 2020, to January 31, 2021.

Results: A total of 199 patients were admitted to the hospital for laboratory-confirmed COVID-19 infection during the study period and 61 patients (31%) received ≥ 1 antibiotic on hospital admission and 138 (69%) did not receive antibiotics. Forty-seven patients (77%) had antibiotics discontinued by the ASP team within 72 hours of admission. Of the 199 admitted, 6 (3%) had microbiologically confirmed bacterial coinfection. Pseudomonas aeruginosa was the most common organism (3 sputum cultures) followed by Klebsiella oxytoca (2 sputum cultures). Sixteen patients (8%) developed a nosocomial infection during their hospital stay.

Conclusions: Up to 31% of patients hospitalized for COVID-19 infection received empiric antibiotic treatment for concern of bacterial coinfection. Pharmacist-led ASP led to early discontinuation of antibiotics in many patients. A thorough clinical workup to determine the risk of bacterial coinfection in patients with COVID-19 is important before starting empiric antibiotic therapy. It is essential to continue promoting the ASP during the COVID-19 pandemic to ensure responsible antibiotic use and prevent antimicrobial resistance.

背景:在新冠肺炎大流行期间,观察到经验性抗生素治疗的使用显著增加,尤其是在新冠肺炎住院患者中。改进抗生素处方是抗菌药物管理计划(ASP)的主要目标之一。ASP药剂师的执业范围允许改变抗感染疗法。方法:我们旨在描述内华达州南部退伍军人事务医疗保健系统新冠肺炎住院患者的抗生素处方,并确定该患者群体中细菌合并感染的流行率。我们对2020年11月1日至2021年1月31日入院的患者进行了回顾性图表审查。结果:研究期间,共有199名患者因实验室确诊的新冠肺炎感染入院,61名患者(31%)入院时接受了≥1种抗生素治疗,138名患者(69%)未接受抗生素治疗。47名患者(77%)在入院后72小时内被ASP团队停用抗生素。在199名入院患者中,有6人(3%)经微生物证实存在细菌共感染。铜绿假单胞菌是最常见的细菌(3种痰培养物),其次是氧化克雷伯菌(2种痰培养)。16名患者(8%)在住院期间发生医院感染。结论:高达31%的新冠肺炎感染住院患者因细菌合并感染而接受了经验性抗生素治疗。药剂师领导的ASP导致许多患者提前停用抗生素。在开始经验性抗生素治疗之前,彻底的临床检查以确定新冠肺炎患者细菌合并感染的风险是重要的。在新冠肺炎大流行期间继续推广ASP至关重要,以确保负责任地使用抗生素并防止抗微生物耐药性。
{"title":"Pharmacist-Led Antimicrobial Stewardship and Antibiotic Use in Hospitalized Patients With COVID-19.","authors":"Selena N Pham,&nbsp;Taylor M Hori,&nbsp;Ashfaq Shafiq","doi":"10.12788/fp.0380","DOIUrl":"10.12788/fp.0380","url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, a significant increase in the use of empiric antibiotic therapy has been observed especially in patients hospitalized with COVID-19. Improving antibiotic prescribing is one of the main goals of the antimicrobial stewardship program (ASP). The ASP pharmacists have a scope of practice that authorizes changes in anti-infective therapy.</p><p><strong>Methods: </strong>We aimed to describe antibiotic prescribing in patients hospitalized with COVID-19 at Veterans Affairs Southern Nevada Healthcare System with a pharmacist-led ASP and to determine the prevalence of bacterial coinfection in this patient population. We performed a retrospective chart review of patients admitted to the facility from November 1, 2020, to January 31, 2021.</p><p><strong>Results: </strong>A total of 199 patients were admitted to the hospital for laboratory-confirmed COVID-19 infection during the study period and 61 patients (31%) received ≥ 1 antibiotic on hospital admission and 138 (69%) did not receive antibiotics. Forty-seven patients (77%) had antibiotics discontinued by the ASP team within 72 hours of admission. Of the 199 admitted, 6 (3%) had microbiologically confirmed bacterial coinfection. <i>Pseudomonas aeruginosa</i> was the most common organism (3 sputum cultures) followed by <i>Klebsiella oxytoca</i> (2 sputum cultures). Sixteen patients (8%) developed a nosocomial infection during their hospital stay.</p><p><strong>Conclusions: </strong>Up to 31% of patients hospitalized for COVID-19 infection received empiric antibiotic treatment for concern of bacterial coinfection. Pharmacist-led ASP led to early discontinuation of antibiotics in many patients. A thorough clinical workup to determine the risk of bacterial coinfection in patients with COVID-19 is important before starting empiric antibiotic therapy. It is essential to continue promoting the ASP during the COVID-19 pandemic to ensure responsible antibiotic use and prevent antimicrobial resistance.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584410/pdf/fp-40-06-178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of ChatGPT and Large Language Models in Medicine and Health Care: Benefits and Pitfalls. ChatGPT和大型语言模型在医学和医疗保健中的应用:好处和陷阱。
Pub Date : 2023-06-01 Epub Date: 2023-06-16 DOI: 10.12788/fp.0386
Andrew A Borkowski, Colleen E Jakey, Stephen M Mastorides, Ana L Kraus, Gitanjali Vidyarthi, Narayan Viswanadhan, Jose L Lezama

Background: The use of large language models like ChatGPT is becoming increasingly popular in health care settings. These artificial intelligence models are trained on vast amounts of data and can be used for various tasks, such as language translation, summarization, and answering questions.

Observations: Large language models have the potential to revolutionize the industry by assisting medical professionals with administrative tasks, improving diagnostic accuracy, and engaging patients. However, pitfalls exist, such as its inability to distinguish between real and fake information and the need to comply with privacy, security, and transparency principles.

Conclusions: Careful consideration is needed to ensure the responsible and ethical use of large language models in medicine and health care. The development of [artificial intelligence] is as fundamental as the creation of the microprocessor, the personal computer, the Internet, and the mobile phone. It will change the way people work, learn, travel, get health care, and communicate with each other. Bill Gates1.

背景:像ChatGPT这样的大型语言模型在医疗保健环境中越来越受欢迎。这些人工智能模型基于大量数据进行训练,可用于各种任务,如语言翻译、摘要和回答问题。观察:大型语言模型有可能通过帮助医疗专业人员完成管理任务、提高诊断准确性和吸引患者来彻底改变行业。然而,也存在一些陷阱,比如它无法区分真实和虚假信息,以及需要遵守隐私、安全和透明原则。结论:需要仔细考虑,以确保在医学和医疗保健中负责任和合乎道德地使用大型语言模型。[人工智能]的发展与微处理器、个人电脑、互联网和手机的发明一样重要。它将改变人们的工作、学习、旅行、获得医疗保健以及相互交流的方式。比尔·盖茨1。
{"title":"Applications of ChatGPT and Large Language Models in Medicine and Health Care: Benefits and Pitfalls.","authors":"Andrew A Borkowski,&nbsp;Colleen E Jakey,&nbsp;Stephen M Mastorides,&nbsp;Ana L Kraus,&nbsp;Gitanjali Vidyarthi,&nbsp;Narayan Viswanadhan,&nbsp;Jose L Lezama","doi":"10.12788/fp.0386","DOIUrl":"https://doi.org/10.12788/fp.0386","url":null,"abstract":"<p><strong>Background: </strong>The use of large language models like ChatGPT is becoming increasingly popular in health care settings. These artificial intelligence models are trained on vast amounts of data and can be used for various tasks, such as language translation, summarization, and answering questions.</p><p><strong>Observations: </strong>Large language models have the potential to revolutionize the industry by assisting medical professionals with administrative tasks, improving diagnostic accuracy, and engaging patients. However, pitfalls exist, such as its inability to distinguish between real and fake information and the need to comply with privacy, security, and transparency principles.</p><p><strong>Conclusions: </strong>Careful consideration is needed to ensure the responsible and ethical use of large language models in medicine and health care. <i>The development of [artificial intelligence] is as fundamental as the creation of the microprocessor, the personal computer, the Internet, and the mobile phone. It will change the way people work, learn, travel, get health care, and communicate with each other.</i> Bill Gates1.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584408/pdf/fp-40-06-170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Muscle-Related Adverse Events Associated With PCSK9 Inhibitors in a Veteran Population. 退伍军人中PCSK9抑制剂相关的肌肉相关不良事件
Joseph Cencetti, Callie Abramowitz, Heather Spoonhower
BackgroundStatins and PCSK9 inhibitors (PCSK9i) are used to lower low-density lipoprotein cholesterol and reduce cardiovascular events, yet some patients are unable to tolerate statin therapy due to muscle-related adverse events (AEs). The effect of PCSK9i on muscle-related AEs is not well studied, and available data show inconsistent incidence rates.MethodsThe primary study outcome was to determine the percentage of patients who developed muscle-related PCSK9i AEs. A secondary outcome was to analyze data based on 4 subgroups: tolerated a full PCSK9i dose; tolerated alternative PCSK9i following initial intolerance; required a PCSK9i dose reduction, or discontinued PCSK9i. In addition, the percentage of statin- and/or ezetimibe-intolerant patients in these 4 groups was determined. Another secondary outcome was the management strategies taken for patients who were on a reduced (monthly) dose of PCSK9i who did not reach their low-density lipoprotein cholesterol goal. Statin intolerance was defined as intolerable skeletal muscle AEs on at least 3 different statins. We conducted a single-center, retrospective review of patients prescribed a PCSK9i between December 1, 2017, and September 1, 2021, at a patient aligned care team clinic at the Wilkes-Barre Veterans Affairs Medical Center.ResultsThe study included 137 veterans. Twenty-four patients (17.5%) developed a muscle-related AE while on a PCSK9i. In predefined subgroups studied, statin intolerance ranged from 68.1% to 100%, ezetimibe intolerance ranged from 41.6% to 83.3%, and both statin and ezetimibe intolerance ranged from 36.3% to 83.3%.ConclusionsIn this study, muscle-related PCSK9i AEs occurred at a similar incidence rate to that reported in previous clinical trials and exceeded the incidence rate reported in the prescribing information for alirocumab and evolocumab. It also appears that patients who have a prior muscle-related intolerance to a statin and/or ezetimibe have a higher likelihood of developing a muscle-related AE to a PCSK9i.
他汀类药物和PCSK9抑制剂(PCSK9i)用于降低低密度脂蛋白胆固醇和减少心血管事件,然而一些患者由于肌肉相关不良事件(ae)而无法耐受他汀类药物治疗。PCSK9i对肌肉相关ae的影响尚未得到很好的研究,现有数据显示发病率不一致。方法主要研究结果是确定发生肌肉相关PCSK9i ae的患者百分比。次要结局是分析基于4个亚组的数据:耐受全剂量PCSK9i;初始不耐受后可耐受替代PCSK9i;需要减少PCSK9i剂量,或停用PCSK9i。此外,确定了这4组中他汀类药物和/或依折替米贝不耐受患者的百分比。另一个次要结果是对未达到低密度脂蛋白胆固醇目标的减少(每月)PCSK9i剂量的患者所采取的管理策略。他汀类药物不耐受被定义为对至少3种不同他汀类药物的骨骼肌不良反应。我们对2017年12月1日至2021年9月1日期间在Wilkes-Barre退伍军人事务医疗中心的患者对齐护理团队诊所使用PCSK9i的患者进行了单中心回顾性评价。结果该研究包括137名退伍军人。24例患者(17.5%)在使用PCSK9i时发生了肌肉相关AE。在预先确定的亚组研究中,他汀类药物不耐受范围从68.1%到100%,依泽替米贝不耐受范围从41.6%到83.3%,他汀类药物和依泽替米贝不耐受范围从36.3%到83.3%。结论在本研究中,肌肉相关PCSK9i ae的发生率与以往临床试验报道的发生率相似,并且超过了alirocumab和evolocumab处方信息中报道的发生率。此外,既往对他汀类药物和/或依zetimibe有肌肉相关不耐受的患者发生PCSK9i肌肉相关AE的可能性更高。
{"title":"Muscle-Related Adverse Events Associated With PCSK9 Inhibitors in a Veteran Population.","authors":"Joseph Cencetti, Callie Abramowitz, Heather Spoonhower","doi":"10.12788/fp.0357","DOIUrl":"https://doi.org/10.12788/fp.0357","url":null,"abstract":"Background\u0000Statins and PCSK9 inhibitors (PCSK9i) are used to lower low-density lipoprotein cholesterol and reduce cardiovascular events, yet some patients are unable to tolerate statin therapy due to muscle-related adverse events (AEs). The effect of PCSK9i on muscle-related AEs is not well studied, and available data show inconsistent incidence rates.\u0000\u0000\u0000Methods\u0000The primary study outcome was to determine the percentage of patients who developed muscle-related PCSK9i AEs. A secondary outcome was to analyze data based on 4 subgroups: tolerated a full PCSK9i dose; tolerated alternative PCSK9i following initial intolerance; required a PCSK9i dose reduction, or discontinued PCSK9i. In addition, the percentage of statin- and/or ezetimibe-intolerant patients in these 4 groups was determined. Another secondary outcome was the management strategies taken for patients who were on a reduced (monthly) dose of PCSK9i who did not reach their low-density lipoprotein cholesterol goal. Statin intolerance was defined as intolerable skeletal muscle AEs on at least 3 different statins. We conducted a single-center, retrospective review of patients prescribed a PCSK9i between December 1, 2017, and September 1, 2021, at a patient aligned care team clinic at the Wilkes-Barre Veterans Affairs Medical Center.\u0000\u0000\u0000Results\u0000The study included 137 veterans. Twenty-four patients (17.5%) developed a muscle-related AE while on a PCSK9i. In predefined subgroups studied, statin intolerance ranged from 68.1% to 100%, ezetimibe intolerance ranged from 41.6% to 83.3%, and both statin and ezetimibe intolerance ranged from 36.3% to 83.3%.\u0000\u0000\u0000Conclusions\u0000In this study, muscle-related PCSK9i AEs occurred at a similar incidence rate to that reported in previous clinical trials and exceeded the incidence rate reported in the prescribing information for alirocumab and evolocumab. It also appears that patients who have a prior muscle-related intolerance to a statin and/or ezetimibe have a higher likelihood of developing a muscle-related AE to a PCSK9i.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46150109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Improving Patient Access to the My HealtheVet Electronic Patient Portal for Veterans. 改善退伍军人使用My HealtheVet电子患者门户的患者访问权限。
Corinne Roberto, Melanie Keiffer, Melanie V. Black, Carol Williams-Suich, Karen Grunewald
BackgroundThe US Department of Veterans Affairs My HealtheVet (MHV) patient portal is a secure online tool that provides patients access to personal health information. Although facilitators exist to encourage veteran registration, barriers to both adoption and use among veterans persist. This quality improvement project sought to improve veteran access to MHV.ObservationsUsing Plan-Do-Study-Act (PDSA) methodology, we identified barriers to registration, evaluated processes for enrollment, and integrated a process improvement champion into a rural primary care clinic workflow. After 3 PDSA cycles, the integration of new processes resulted in increased enrollment and engagement with MHV. Fourteen veterans registered for MHV at the point-of-care in a 3-month time frame.ConclusionsUse of a connected electronic health record platform and implementation of an MHV champion in the outpatient primary care setting improved rural veteran access to personal health information. Audit and feedback on processes that provide access to health information is an important strategy to narrow the gap between veterans who access patient portals and those who do not.
背景美国退伍军人事务部My HealtheVet(MHV)患者门户网站是一个安全的在线工具,为患者提供个人健康信息。尽管存在鼓励退伍军人登记的促进者,但退伍军人在收养和使用方面仍然存在障碍。该质量改进项目旨在改善退伍军人获得MHV.观察的机会。我们使用计划-研究法案(PDSA)方法,确定了注册障碍,评估了注册流程,并将流程改进倡导者纳入农村初级保健诊所的工作流程。在3个PDSA周期后,新流程的整合增加了MHV的注册人数和参与度。在3个月的时间内,14名退伍军人在护理点注册了MHV。结论联网电子健康记录平台的使用和MHV冠军在门诊初级保健环境中的实施改善了农村退伍军人获得个人健康信息的机会。对提供健康信息访问的流程进行审计和反馈是缩小退伍军人访问患者门户网站和不访问患者门户之间差距的重要策略。
{"title":"Improving Patient Access to the My HealtheVet Electronic Patient Portal for Veterans.","authors":"Corinne Roberto, Melanie Keiffer, Melanie V. Black, Carol Williams-Suich, Karen Grunewald","doi":"10.12788/fp.0331","DOIUrl":"https://doi.org/10.12788/fp.0331","url":null,"abstract":"Background\u0000The US Department of Veterans Affairs My HealtheVet (MHV) patient portal is a secure online tool that provides patients access to personal health information. Although facilitators exist to encourage veteran registration, barriers to both adoption and use among veterans persist. This quality improvement project sought to improve veteran access to MHV.\u0000\u0000\u0000Observations\u0000Using Plan-Do-Study-Act (PDSA) methodology, we identified barriers to registration, evaluated processes for enrollment, and integrated a process improvement champion into a rural primary care clinic workflow. After 3 PDSA cycles, the integration of new processes resulted in increased enrollment and engagement with MHV. Fourteen veterans registered for MHV at the point-of-care in a 3-month time frame.\u0000\u0000\u0000Conclusions\u0000Use of a connected electronic health record platform and implementation of an MHV champion in the outpatient primary care setting improved rural veteran access to personal health information. Audit and feedback on processes that provide access to health information is an important strategy to narrow the gap between veterans who access patient portals and those who do not.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42907875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Patient Presenting With Shortness of Breath, Fever, and Eosinophilia. 一名出现呼吸急促、发烧和嗜酸性粒细胞增多症的患者。
S. Varghese, M. Kouma, D. Storey, R. Arasaratnam
A 70-year-old veteran with a history notable for type 2 diabetes mellitus, complicated by peripheral neuropathy and bilateral foot ulceration, and previous pulmonary tuberculosis (treated in June 2013) presented to an outside medical facility with bilateral worsening foot pain, swelling, and drainage of preexisting ulcers. He received a diagnosis of bilateral fifth toe osteomyelitis and was discharged with a 6-week course of IV daptomycin 600 mg (8 mg/kg) and ertapenem 1 g/d. At discharge, the patient was in stable condition. Follow-up was done by our outpatient parenteral antimicrobial therapy (OPAT) team, which consists of an infectious disease pharmacist and the physician director of antimicrobial stewardship who monitor veterans receiving outpatient IV antibiotic therapy.1 Three weeks later as part of the regular OPAT surveillance, the patient reported via telephone that his foot osteomyelitis was stable, but he had a 101 °F fever and a new cough. He was instructed to come to the emergency department (ED) immediately. On arrival, complete blood count (CBC) revealed leukocytosis with elevated eosinophils to 2.67 K/μL compared with 0.86 K/μL (reference range, 0 to 0.5 K/μL) 1 week earlier (eAppendix, available at doi:10.2788 /fp.0336). Renal and liver function were within normal limits. A COVID-19 test was negative. The initial examination was notable for mild respiratory distress with oxygen saturation of 90% on room air and a respiratory rate of 25 breaths/min. A lung examination showed bilateral crackles. He reported no skin rash or mucosal lesions. The patient was placed on 2 L/min of oxygen via nasal cannula. A chest radiograph showed rightsided opacities; however, further computed tomography (CT) chest imaging was significant for bilateral opacities (Figure 1).
一名70岁的退伍军人,有2型糖尿病病史,并发周围神经病变和双侧足部溃疡,既往患有肺结核(2013年6月接受治疗),因双侧足部疼痛、肿胀和原有溃疡引流恶化而被送往外部医疗机构。他被诊断为双侧第五趾骨髓炎,出院后静脉注射达托霉素600 mg(8 mg/kg)和厄他培南1 g/d,疗程6周。出院时,患者情况稳定。我们的门诊肠外抗菌治疗(OPAT)团队进行了随访,该团队由一名传染病药剂师和抗菌管理主任医师组成,他们负责监测接受门诊静脉抗生素治疗的退伍军人。1三周后,作为常规OPAT监测的一部分,患者通过电话报告他的足部骨髓炎稳定,但他发烧101华氏度,并再次咳嗽。他接到指示立即去急诊室。抵达时,全血细胞计数(CBC)显示白细胞增多,嗜酸性粒细胞升高至2.67 K/μL,而一周前为0.86 K/μL(参考范围,0至0.5 K/μ)(eAppendix,可在doi:10.2788/fp.0336上获得)。肾和肝功能在正常范围内。新冠肺炎检测呈阴性。最初的检查是显著的轻度呼吸窘迫,房间空气中的氧饱和度为90%,呼吸频率为25次呼吸/分钟。肺部检查显示双侧有裂纹。他报告没有皮疹或粘膜损伤。通过鼻插管将患者置于2L/min的氧气中。胸部X线片显示右侧不透明;然而,进一步的计算机断层扫描(CT)胸部成像对双侧混浊具有重要意义(图1)。
{"title":"A Patient Presenting With Shortness of Breath, Fever, and Eosinophilia.","authors":"S. Varghese, M. Kouma, D. Storey, R. Arasaratnam","doi":"10.12788/fp.0336","DOIUrl":"https://doi.org/10.12788/fp.0336","url":null,"abstract":"A 70-year-old veteran with a history notable for type 2 diabetes mellitus, complicated by peripheral neuropathy and bilateral foot ulceration, and previous pulmonary tuberculosis (treated in June 2013) presented to an outside medical facility with bilateral worsening foot pain, swelling, and drainage of preexisting ulcers. He received a diagnosis of bilateral fifth toe osteomyelitis and was discharged with a 6-week course of IV daptomycin 600 mg (8 mg/kg) and ertapenem 1 g/d. At discharge, the patient was in stable condition. Follow-up was done by our outpatient parenteral antimicrobial therapy (OPAT) team, which consists of an infectious disease pharmacist and the physician director of antimicrobial stewardship who monitor veterans receiving outpatient IV antibiotic therapy.1 Three weeks later as part of the regular OPAT surveillance, the patient reported via telephone that his foot osteomyelitis was stable, but he had a 101 °F fever and a new cough. He was instructed to come to the emergency department (ED) immediately. On arrival, complete blood count (CBC) revealed leukocytosis with elevated eosinophils to 2.67 K/μL compared with 0.86 K/μL (reference range, 0 to 0.5 K/μL) 1 week earlier (eAppendix, available at doi:10.2788 /fp.0336). Renal and liver function were within normal limits. A COVID-19 test was negative. The initial examination was notable for mild respiratory distress with oxygen saturation of 90% on room air and a respiratory rate of 25 breaths/min. A lung examination showed bilateral crackles. He reported no skin rash or mucosal lesions. The patient was placed on 2 L/min of oxygen via nasal cannula. A chest radiograph showed rightsided opacities; however, further computed tomography (CT) chest imaging was significant for bilateral opacities (Figure 1).","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49654125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medications for Opioid Use Disorder Program in a VA Emergency Department 阿片类药物使用障碍项目在VA急诊科
Jonie J Hsiao
{"title":"Medications for Opioid Use Disorder Program in a VA Emergency Department","authors":"Jonie J Hsiao","doi":"10.12788/fp.0306","DOIUrl":"https://doi.org/10.12788/fp.0306","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73471580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insulin Injection-Site Acanthosis Nigricans: Skin Reactions and Clinical Implications 胰岛素注射部位黑棘皮病:皮肤反应和临床意义
M. Hower
{"title":"Insulin Injection-Site Acanthosis Nigricans: Skin Reactions and Clinical Implications","authors":"M. Hower","doi":"10.12788/fp.0253","DOIUrl":"https://doi.org/10.12788/fp.0253","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89044432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing Opioid Response in Older Veterans in the Post-Acute Setting 老年退伍军人急性后阿片类药物反应的特征
Victoria D. Powell
Background: Opioids often are used in post-acute care (PAC) settings, although there is a lack of evidence of sustained pain reduction and improved function. There are subgroups of individuals whose pain does not respond well to opioids yet report these agents as highly beneficial. We aimed to classify opioid responsiveness among veterans residing in a US Department of Veterans Affairs community living center PAC unit. Methods: This observational, cross-sectional study used barcode medication administration data followed by retrospective chart review. We determined opioid responsiveness along a continuum during 4 nonconsecutive days in 2016 and 2017. We defined opioid responsiveness as the mean change in pre- and postopioid pain ratings using the 0 to 10 scale over the 24-hour observation period (ie, mean ∆ score). The chart review identified correlates of opioid responsiveness adjusting for mean pre-opioid pain ratings. Results: Among the 41 residents who received opioids for at least moderate pain (≥ 4 of 10), the average response was highly variable (range, 0.5 - 6.3). Response did not correlate with demographic variables, indication for admission, or medical comorbidities, including cancer diagnosis. The presence of any psychiatric diagnosis ( P = .03), pain service consult ( P = .03), and higher opioid dosage ( P = .002) was significantly associated with poorer response. Conclusions: This pilot study classified opioid response on a continuum using a scalable administrative data source. Despite receiving higher dosages and more specialist consultations, some veterans’ pain responds poorly to opioids. Psychiatric comorbidity seems to increase this risk. Future studies in larger, more representative populations are necessary to confirm these findings to develop personalized pain management strategies that mitigate risks of opioids. its This article may discuss unlabeled or inves- tigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combina- tions—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
背景:阿片类药物经常用于急性后护理(PAC)环境,尽管缺乏持续减轻疼痛和改善功能的证据。有些个体对阿片类药物的疼痛反应不佳,但报告这些药物非常有益。我们的目的是对居住在美国退伍军人事务部社区生活中心PAC单元的退伍军人的阿片类药物反应性进行分类。方法:本观察性横断面研究采用条形码给药数据,并进行回顾性图表回顾。我们在2016年和2017年连续测定了4天的阿片类药物反应性。我们将阿片类药物反应性定义为在24小时观察期内使用0到10分制的阿片类药物前和阿片类药物后疼痛评分的平均变化(即平均∆评分)。图表回顾确定了阿片类药物反应性调整平均阿片类药物前疼痛评分的相关性。结果:在41名接受阿片类药物治疗至少中度疼痛的居民(≥4 / 10)中,平均反应变化很大(范围为0.5 - 6.3)。反应与人口统计学变量、入院指征或医学合并症(包括癌症诊断)无关。任何精神科诊断(P = .03)、疼痛服务咨询(P = .03)和较高阿片类药物剂量(P = .002)的存在与较差的反应显著相关。结论:这项试点研究使用可扩展的管理数据源对阿片类药物反应进行连续分类。尽管接受了更高的剂量和更多的专家咨询,但一些退伍军人对阿片类药物的疼痛反应不佳。精神疾病似乎增加了这种风险。未来有必要在更大、更有代表性的人群中进行研究,以证实这些发现,从而制定个性化的疼痛管理策略,减轻阿片类药物的风险。本文可能讨论某些药物的未标记或研究用途。在给患者进行药物治疗之前,请查看特定药物或药物组合的完整处方信息,包括适应症、禁忌症、警告和不良反应。
{"title":"Characterizing Opioid Response in Older Veterans in the Post-Acute Setting","authors":"Victoria D. Powell","doi":"10.12788/fp.0229","DOIUrl":"https://doi.org/10.12788/fp.0229","url":null,"abstract":"Background: Opioids often are used in post-acute care (PAC) settings, although there is a lack of evidence of sustained pain reduction and improved function. There are subgroups of individuals whose pain does not respond well to opioids yet report these agents as highly beneficial. We aimed to classify opioid responsiveness among veterans residing in a US Department of Veterans Affairs community living center PAC unit. Methods: This observational, cross-sectional study used barcode medication administration data followed by retrospective chart review. We determined opioid responsiveness along a continuum during 4 nonconsecutive days in 2016 and 2017. We defined opioid responsiveness as the mean change in pre- and postopioid pain ratings using the 0 to 10 scale over the 24-hour observation period (ie, mean ∆ score). The chart review identified correlates of opioid responsiveness adjusting for mean pre-opioid pain ratings. Results: Among the 41 residents who received opioids for at least moderate pain (≥ 4 of 10), the average response was highly variable (range, 0.5 - 6.3). Response did not correlate with demographic variables, indication for admission, or medical comorbidities, including cancer diagnosis. The presence of any psychiatric diagnosis ( P = .03), pain service consult ( P = .03), and higher opioid dosage ( P = .002) was significantly associated with poorer response. Conclusions: This pilot study classified opioid response on a continuum using a scalable administrative data source. Despite receiving higher dosages and more specialist consultations, some veterans’ pain responds poorly to opioids. Psychiatric comorbidity seems to increase this risk. Future studies in larger, more representative populations are necessary to confirm these findings to develop personalized pain management strategies that mitigate risks of opioids. its This article may discuss unlabeled or inves- tigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combina- tions—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77513052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1